<DOC>
	<DOCNO>NCT00438737</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor.Drugs use chemotherapy , leucovorin , oxaliplatin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving cetuximab together combination chemotherapy bevacizumab surgery may make tumor small reduce amount normal tissue need remove . Giving treatment surgery may kill tumor cell remain surgery . PURPOSE : This randomized phase II trial study side effect well give cetuximab together leucovorin , oxaliplatin , fluorouracil work without bevacizumab treat patient resectable liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Cetuximab , Leucovorin , Oxaliplatin , Fluorouracil With Without Bevacizumab Treating Patients With Resectable Liver Metastases From Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare safety activity neoadjuvant adjuvant cetuximab , leucovorin calcium , oxaliplatin , fluorouracil v without bevacizumab patient resectable liver metastasis secondary colorectal cancer . OUTLINE : This open-label , randomize , multicenter study . Patient stratify accord participate center plan liver resection ( major [ ≥ 3 segment ] v minor [ &lt; 3 segment ] ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive leucovorin calcium IV 2 hour oxaliplatin IV 2 hour day 1 fluorouracil IV 46 hour ( FOLFOX ) begin day 1 . Patients also receive cetuximab IV 1-2 hour day 1 8 . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Between 3-5 week completion FOLFOX cetuximab , patient undergo liver resection . Beginning 4-8 week surgery , patient receive another 6 course FOLFOX cetuximab neoadjuvant therapy . - Arm II : Patients receive FOLFOX cetuximab arm I bevacizumab IV 30-90 minute day 1 . Treatment repeat every 14 day 6 courses* absence disease progression unacceptable toxicity . NOTE : *Patients receive bevacizumab course 6 Between 3-5 week completion FOLFOX , cetuximab , bevacizumab , patient undergo liver resection . Beginning 4-8 week surgery , patient receive another 6 course FOLFOX , cetuximab , bevacizumab neoadjuvant therapy . After completion study treatment , patient follow every 3 month 2 year every 6 month least 3 year . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic colorectal cancer , meet follow criterion : Metachronous synchronous liver metastases Metastases potentially completely resectable No requirement resection combine cryotherapy radiofrequency ablation Must undergone complete resection ( R0 ) primary tumor within past 4 week Measurable liver metastases No evidence extrahepatic disease 1 2 resectable lung metastasis allow PATIENT CHARACTERISTICS : WHO performance status 01 Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 9 g/dL WBC &gt; 3,000/mm³ Creatinine &lt; 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN AST ALT &lt; 5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant proteinuria ( i.e. , protein &gt; 500 mg/24hour urine collection ) No know allergy study drug ( include excipients ) relate compound , include hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibodies No bleed diathesis coagulopathy No peripheral neuropathy &gt; grade 1 No serious nonhealing wound , ulcer , bone fracture No clinically significant cardiovascular disease , include follow : Uncontrolled hypertension New York Heart Association class IIIV congestive heart failure Unstable angina pectoris within past 12 month Peripheral vascular disease ≥ grade 2 Serious cardiac arrhythmia require medication Myocardial infarction within past 12 month Cerebrovascular accident transient ischemic attack within past 12 month No symptomatic diverticulitis know gastroduodenal ulceration No significant traumatic injury within past 4 week No know alcohol drug abuse No psychological , familial , social , geographical condition would preclude study compliance No significant disease would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy metastatic disease At least 1 month since prior major surgical procedure open biopsy More 30 day since prior participation another clinical study Prior adjuvant chemotherapy primary cancer allow provide follow criterion meet : At least 12 month since prior oxaliplatincontaining adjuvant therapy No persistent neuropathy No prior therapy target epidermal growth factor receptor vascular endothelial growth factor ( VEGF ) /VEGF receptor No concurrent regular use acetylsalicylic acid ( &gt; 325 mg/day ) nonsteroidal antiinflammatory drug No concurrent fulldose anticoagulation No concurrent prophylactic hematopoietic growth factor No concurrent allopurinol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>